Why the Clock Kills More Deals Than the Competition

Timing emerged as one of the biggest threats to the success of build-to-buy models. Ramin Mousavi likened the model to a long engagement. “You enter into an agreement where the wedding is down the road. But the more you get to know each other, the more you find things you don’t like,” he said. “And the more successful you are, the worse it feels, because in an open market, you’d likely get a better deal.” Makower was candid: “I don’t know many build-to-buys that have actually consummated in the end.” For more details read here: https://www.slideserve.com/James1267/why-the-clock-kills-more-deals-than-the-competition

Comments

Post a Comment

Popular posts from this blog

Big Tech and Big Pharma: How Medtech Can Bridge the Gap

As technologies evolve and  healthcare innovation  accelerates, the traditional boundaries separating medtech, big tech, and big pharma are increasingly blurry — but the cultural and strategic gaps between them remain. At LSI USA ’25, panelists Juan-Pablo Mas (Action Potential Venture Capital), Nishant Doctor (Surf Therapeutics), and Jordi Parramon (Nexus NeuroTech Ventures) joined moderator Katie Elias to examine how medtech can better align with  big tech and big pharma  to drive innovation forward. The conversation centered on key differences in development strategy, investor expectations, and business timelines — critical challenges that arise when building partnerships or raising capital across sectors. As medtech companies seek broader platforms and more ambitious outcomes, understanding and navigating these differences becomes essential for effective cross-sector collaboration and long-term success. Understanding the Evidence Gap A major area of divergence bet...
Read more